UBS Group’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-26,400
Closed -$704K – 10291
2024
Q4
$704K Hold
26,400
– – ﹤0.01% 5605
2024
Q3
$753K Buy
+26,400
New +$672K ﹤0.01% 4900
2021
Q1
– Sell
-15,000
Closed -$1.01M – 9053
2020
Q4
$1.01M Buy
+15,000
New +$813K ﹤0.01% 4019

Other funds holding CSTL

UBS Group's CSTL Position: Q3 2026 in Review

UBS Group reduced its Castle Biosciences (CSTL) stake by 13% in Q3 2026, selling an estimated $344K and leaving 77,983 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #4722.

UBS Group first reported a position in CSTL in Q3 2019 and has held it in 29 quarters since. The position peaked at $21.7M in Q4 2024. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • UBS Group held 77,983 shares of Castle Biosciences worth $2.77M as of Q3 2026.
  • UBS Group sold 11,385 Castle Biosciences shares in Q3 2026, an estimated $344K.
  • Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4722 holding.
  • UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 29 quarters since.
  • UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.